Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S (NASDAQ: EVAX) is a clinical-stage TechBio company that regularly issues news on its AI-Immunology™ powered vaccine and immunotherapy programs. The company’s updates highlight progress across cancer, infectious disease and autoimmune disease research, making EVAX news relevant for investors and followers of AI-driven biotechnology.
News from Evaxion often covers clinical and preclinical data from its oncology pipeline, including the personalized cancer vaccine EVX-01 for advanced melanoma and the ERV-based off-the-shelf cancer vaccine candidate EVX-04 for acute myeloid leukemia. Releases may detail biomarker findings, immune response data, and presentations at major scientific meetings such as oncology and hematology conferences.
On the infectious disease side, Evaxion publishes updates on vaccine candidates like the gonorrhea program EVX-B2 and the CMV vaccine program EVX-V1. These announcements can include preclinical efficacy data, discovery of novel AI-identified antigens, and progress in optimizing vaccine components such as AI-optimized glycoprotein antigens. Business development news may also describe option decisions, out-licensing arrangements and partnership discussions with pharmaceutical companies.
Corporate and financial communications form another important part of the EVAX news flow. Evaxion reports business updates, financial results, capital raises, changes to its Articles of Association related to share capital, and its financial calendar through press releases and accompanying SEC Form 6-K filings. The company also issues announcements about strategic milestones, such as expanding AI-Immunology™ into autoimmune diseases or enhancing the platform with automated vaccine design modules.
This news page aggregates these items so readers can follow Evaxion’s scientific progress, platform evolution, partnership activity and corporate developments in one place. For those tracking AI-based drug discovery, cancer vaccines and infectious disease vaccines, the EVAX news feed provides ongoing insight into how Evaxion applies its AI-Immunology™ platform across multiple therapeutic areas.
Evaxion (NASDAQ: EVAX) will provide a business update and report its third quarter 2025 financial results on Friday, October 31, 2025 before Nasdaq open. Management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present results and take questions. The event is free and open to the public; participants must register in advance to receive dial-in numbers and a unique PIN for verbal questions. The call can be accessed 15 minutes before the start. A webcast link will be provided and a recording will be posted on the company website shortly after the event. Investor relations contact: Mads Kronborg, Vice President Investor Relations & Communication.
Evaxion (NASDAQ: EVAX) raised $7.2 million through an at-the-market share sale ($4.5M) and investor warrant exercises ($2.7M), and reports a total cash inflow of $14.7M since the end of Q2 2025. Combined with a $7.5M license payment from MSD for EVX-B3 in September 2025, Evaxion says it now has cash to fund operations and R&D into the second half of 2027 (extended from H1 2027).
The company reports an expected operational cash spend of $14M in 2025, a reduction of outstanding warrants by 1.0M to 2.8M total, and a weighted average warrant exercise price of $10.94. A debt-to-equity conversion reduced prior debt by $4.1M.
Evaxion (NASDAQ: EVAX) appointed Dr Helen Tayton-Martin as Chief Executive Officer, effective 24 November 2025. She will simultaneously resign from Evaxion’s Board.
Dr Tayton-Martin holds a Ph.D. in molecular immunology and an MBA, co-founded Adaptimmune and spent 17 years there in senior operating and business roles overseeing transatlantic growth, partnerships and financing through a Nasdaq IPO. Evaxion highlighted recent commercial progress including the out-license of EVX-B3 to MSD and presentation of EVX-01 data at ESMO.
Birgitte Rønø will return to her role as Chief Scientific Officer. Jens Bitsch-Norhave will join the Board as adviser and observer and intends to seek election at the Annual General Meeting in 2026.
Evaxion (NASDAQ: EVAX) reported two-year phase 2 results for its AI-designed personalized cancer vaccine EVX-01 in advanced melanoma on October 17, 2025.
Key outcomes: ORR 75% (12/16 patients), including 4 complete responses; 92% of patients still responding at 24 months; tumor reduction in 15/16 patients; 81% of vaccine targets induced T-cell responses; 54% experienced deepened responses; treatment was well tolerated. Data presented at ESMO 2025; webinar scheduled October 22, 2025.
Evaxion (NASDAQ: EVAX) will present two-year phase 2 data for its AI-designed personalized cancer vaccine EVX-01 at ESMO Congress 2025 on October 17, 2025 (oral session) with a follow-up webinar on October 22, 2025. The presentation covers two-year clinical efficacy, immunogenicity and safety, including best overall response, deepened response/conversion rates, durability of response, and T-cell breadth/magnitude/duration after booster dosing.
Earlier interim data reported a 69% overall response rate, tumor target lesion reduction in 15 of 16 patients, a correlation between AI predictions and immune responses (p=0.00013), and that 80% of vaccine targets triggered tumor-specific immune responses. The trial tests EVX-01 plus KEYTRUDA® in advanced melanoma; Evaxion will be available at booth #3035 for discussions.
Evaxion (NASDAQ: EVAX) launches an automated vaccine design module for its AI-Immunology™ platform that combines target discovery and design into an end-to-end workflow. The module aims to ensure correct antigen sequence and conformation, improve vaccine quality, and reduce design time from months to days, with associated cost savings. The tool can be applied to both new vaccines and optimization of approved vaccines. Evaxion will present validation data and test results at the World Vaccine Congress Europe in Amsterdam on October 15, 2025.
Evaxion (NASDAQ: EVAX) will present new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.
The poster (Abstract #605, Poster #605) is titled "Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and Pembrolizumab in advanced melanoma patients" and will be presented on November 7, 2025, 5:10–6:35 p.m. ET by Michail Angelos Pavlidis. Two-year efficacy data from the same phase 2 trial will be presented orally at ESMO 2025 on October 17, 2025. The phase 2 study evaluates EVX-01 plus KEYTRUDA (pembrolizumab) in advanced melanoma with individualized vaccines per patient.
Evaxion (NASDAQ: EVAX) has successfully out-licensed its vaccine candidate EVX-B3 to MSD (Merck) in a significant deal worth up to $592 million plus royalties. The agreement includes an immediate $7.5 million cash payment, extending Evaxion's cash runway to H1 2027.
MSD will take full responsibility for EVX-B3's development, which targets a pathogen associated with serious medical complications and currently has no available vaccines. The deal validates Evaxion's AI-Immunology™ platform technology.
Additionally, MSD has extended its evaluation period for a second vaccine candidate, EVX-B2 (targeting Gonorrhea), with a licensing decision expected in H1 2026. If exercised, this option would bring an additional $2.5 million upfront payment plus similar milestone payments and royalties.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced its participation in multiple scientific and investor conferences across the US, Europe, and Asia during H2 2025.
The company's Chief Scientific Officer and interim CEO Birgitte Rønø highlighted that their two-year clinical data for the personalized cancer vaccine EVX-01 has been selected for oral presentation at the ESMO congress in October. The conference schedule includes prestigious events such as the Vaccine Congress in Kyoto, HC Wainwright Global Investment Conference in New York, and the World Vaccine Congress Europe in Amsterdam.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, reported Q2 2025 financial results and business updates. Key highlights include completion of EVX-01 phase 2 trial treatments, with full two-year clinical efficacy data to be presented at ESMO Congress in October 2025. The company received recognition through a Gates Foundation grant for polio vaccine development and expanded its pipeline with EVX-B4 for Group A Streptococcus.
Financial position improved with $14.7 million in cash as of June 30, 2025, sufficient until mid-2026. The company converted €3.5 million of EIB debt to equity at a 89% premium. Q2 2025 resulted in a net loss of $4.8 million ($0.02 per share), compared to $6.2 million loss in Q2 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year.